Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Helixmith Co Ltd (Helixmith) is a biotechnology company that develops gene therapy products and natural nutraceuticals. The company's pipeline products include Engensis (VM202) gene therapy drug that provides fundamental treatment through tissue regeneration, which treats diabetic peripheral neuropathy, amyotrophic lateral sclerosis, diabetic foot ulcer, claudication, charcot marie tooth disease and coronary artery disease. It also offers NM101 for peripheral neuropathy and pain; NM301 targets amyotrophic lateral sclerosis; VM507 treats chronic and acute renal disease. Helixmith offers contract development and manufacturing services, analytical and clinical research organization services and consulting services in natural medicine, health functional food and cosmetic products using botanical sources. The company operates in South Korea and the US. Helixmith is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
21, Magokjungang 8-Ro 7-Gil, Gangseo-Gu, Seoul, 07794
Website
helixmith.com
Telephone
82 2 21027200
No of Employees
44
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
084990 (KDQ)
Revenue (2024)
$1.8M
-47.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
97.2%
(2024 vs 2023)
Market Cap*
$213.9M
Net Profit Margin (2024)
XYZ
94.6%
(2024 vs 2023)
* As of and is in US$
Helixmith Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Gene Therapy |
| Engensis (VM202): |
| Amyotrophic Lateral Sclerosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Helixmith Co Ltd | Daihan Pharm Co Ltd | Ctcbio Inc | iNtRON Biotechnology Inc | Genexine Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Hwaseong | Seongnam | Seoul |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 44 | 737 | 257 | 77 | 68 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Song-Sun Chang | Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer